← ANALYST RATINGS · TIPRANKS
Bausch + Lomb Corporation (BLCO): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy4 Hold1 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $20.56, the highest $24.00, the lowest $16.00. The average is +24.7% from the last price of $16.49.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $18.50 → $16.50−10.8% | Hold | +0.1% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.00 → $16.50−13.2% | Hold | +0.1% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $19.00 → $16.50−13.2% | Hold | +0.1% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $18.00 → $16.00−11.1% | Hold | −3.0% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $20.00 → $17.00−15.0% | Hold | +3.1% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 → $17.00−10.5% | Hold | +3.1% | Reiterated | 13.10.26on TipRanks 08:06 | — | |
| Douglas Miehm★★★★★★★★★★#2559 · hits 51% · avg +5.3% | RBC Capital | $21.00 | Buy | +27.3% | Reiterated | 08.10.26on TipRanks 08:25 | −0.7%next day +0.3% · 5 days −2.6% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $24.00 | Buy | +45.5% | Initiated | 07.10.26on TipRanks 03:55 | +1.2%next day −0.7% · 5 days −6.5% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $20.00 → $21.00+5.0% | Buy | +27.3% | Assigned | 05.10.26on TipRanks 07:21 | −0.3%next day −0.5% · 5 days −6.8% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $18.00 | Hold | +9.2% | Reiterated | 18.09.26on TipRanks Sep 21 04:50 | +0.3%next day −1.8% · 5 days −1.2% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $24.00 | Buy | +45.5% | Initiated | 09.09.26on TipRanks 08:20 | +0.8%next day −0.7% · 5 days −3.0% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $21.00 | Buy | +27.3% | Reiterated | 28.08.26on TipRanks 06:25 | +0.3%next day +2.2% · 5 days +5.1% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $16.00 | Hold | −3.0% | Reiterated | 25.08.26on TipRanks 07:13 | −0.7%next day 0.0% · 5 days +4.2% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | — | Sell | — | Reiterated | 30.07.26on TipRanks 12:33 | +3.2%next day −1.2% · 5 days −7.4% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $17.00 | Hold | +3.1% | Reiterated | 30.07.26on TipRanks 09:06 | +3.2%next day −1.2% · 5 days −7.4% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $21.00 → $23.00+9.5% | Buy | +39.5% | Initiated | 30.07.26on TipRanks Jul 29 14:38 | −0.9%next day +3.2% · 5 days −2.1% | ↗ |
| David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% | Needham | — | Hold | — | Reiterated | 29.07.26on TipRanks 14:38 | −0.9%next day +3.2% · 5 days −2.1% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $21.00 | Hold | +27.3% | Reiterated | 14.07.26on TipRanks Jul 15 16:35 | −1.9%next day +1.6% · 5 days +0.7% | ↗ |
| Pito Chickering★★★★★★★★★★#1500 · hits 61% · avg +9.8% | Deutsche Bank | $18.00 → $16.00−11.1% | Hold | −3.0% | Reiterated | 30.04.26on TipRanks 09:15 | +2.7%next day +2.3% · 5 days −1.7% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $13.00 → $16.00+23.1% | Hold | −3.0% | Reiterated | 30.10.25on TipRanks 09:00 | −1.0%next day −1.6% · 5 days +4.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Bausch + Lomb Corporation
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $20.22 at a price of $17.11 (+18.2%); now: $20.56 at $16.49 (+24.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 7 | 5 | 5 | 7 | 8 | 7 |
| Hold | 10 | 9 | 7 | 7 | 8 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.21 (from $0.17 to $0.26). Last quarter: $0.15.
Sales
Next quarter’s sales estimate — $1.4B (from $1.4B to $1.4B). Last quarter: $1.4B.
Best top-analyst consensus in the sector · Healthcare
About Bausch + Lomb Corporation
- CEO: Thomas J. Appio
- Employees: 13,000
- 520 Applewood Crescent, Vaughan, ON, L4K 4B4, CA
- www.bausch.com
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Data from the stock’s TipRanks forecast page, read 79 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗